Dublin, Ireland, and Riyadh, Saudi Arabia, 5th of August 2024 – Zyme Biotech (www.zymebiotech.com), a global consulting firm specializing in pharmaceutical manufacturing solutions, proudly announces its strategic expansion into the Saudi Arabian biotech market. This ambitious initiative is set to create 150 technical and consulting roles over the next four years, spanning both Ireland and Saudi Arabia.
This expansion is a pivotal moment for Zyme Biotech, underscoring its dedication to global pharmaceutical manufacturing excellence. The newly created roles will encompass project management, technical consulting, and advanced manufacturing, directly supporting Saudi Arabia's burgeoning biotech sector.
In a significant milestone, Zyme Biotech has been selected as the project management partner for the Vaccine Industrial Company (VIC) (www.vaccine.com.sa). The announcement was made during a contract signing at the Irish embassy in Riyadh on the 5th of August, attended by distinguished guests, including the Irish Ambassador to the Kingdom of Saudi Arabia. This high-profile project will oversee the construction of the largest vaccine production facility in the Middle East, highlighting Zyme Biotech’s prowess in technical consulting and project management.
John Ward, Director of Zyme Biotech, stated, “We are thrilled to expand into Saudi Arabia, a region ripe with potential for biotech innovation. Our appointment as the project management partner for the Middle East’s largest vaccine facility is a tremendous opportunity. Our collaboration with VIC underscores our commitment to enhancing global pharmaceutical production through advanced manufacturing processes. Inspired by Vision 2030, we are dedicated to contributing to the region’s evolution into a global biotech hub.”
The new vaccine facility, set to be built in Sudair City, aims to bolster the pharmaceutical security system and localize the production of vaccines and vital medicines in the Kingdom of Saudi Arabia. VIC will ensure a steady supply of essential vaccines and support public health initiatives across the Middle East, leveraging cutting-edge technology and adhering to the highest standards of quality and safety.
Ambassador of Ireland to Saudi Arabia Gerry Cunningham stated “Ireland is acknowledged as a global hub for pharmaceutical manufacturing, research and innovation, due in part to Government support and to indigenous companies such as Zyme Biotech who play a critical and innovative role in delivering projects to successfully meet the most demanding specifications from their multinational clients.
Today we are delighted to host both Zyme Biotech and Saudi Arabia’s Vaccine Industrial Company as they embark on a new partnership which will in turn localise and establish the Kingdom as a major biotechnology and pharmaceutical manufacturer, in line with the aspirations of Vision 2030, while further boosting the growing exchange in technology and expertise between the Kingdom of Saudi Arabia and Ireland.”
Zyme Biotech is committed to propelling biotechnology forward with a comprehensive suite of services, including operational excellence, AI-driven digital transformation, strategic consulting, and validation services. The company’s dedication to sustainability and innovation aligns seamlessly with Saudi Arabia’s Vision 2030, aiming to nurture a knowledge-based economy and support the growth of the biotech sector.
About Zyme Biotech: Zyme Biotech is a global consulting firm specializing in pharmaceutical manufacturing solutions, dedicated to advancing healthcare through innovation and collaboration. Headquartered in Dublin, Ireland, Zyme Biotech offers technical consulting services on a global scale.
About Vaccine Industrial Company: Vaccine Industrial Company (VIC) is at the forefront of the biotechnology and pharmaceutical industry in the Middle East, producing high-quality vaccines. VIC’s mission is to enhance public health and ensure the availability of essential vaccines through advanced technology and robust production.
